- Home
- CCCC vs LPSN Comparison
CCCC vs LPSN Comparison
Compare CCCC & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- LPSN
- Stock Information
- Founded
- CCCC 2015
- LPSN 1995
- Country
- CCCC United States
- LPSN United States
- Employees
- CCCC N/A
- LPSN N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- LPSN EDP Services
- Sector
- CCCC Health Care
- LPSN Technology
- Exchange
- CCCC Nasdaq
- LPSN Nasdaq
- Market Cap
- CCCC 104.4M
- LPSN 97.6M
- IPO Year
- CCCC 2020
- LPSN 2000
- Fundamental
- Price
- CCCC $2.46
- LPSN $0.99
- Analyst Decision
- CCCC Buy
- LPSN Hold
- Analyst Count
- CCCC 2
- LPSN 1
- Target Price
- CCCC $8.00
- LPSN N/A
- AVG Volume (30 Days)
- CCCC 1.5M
- LPSN 8.1M
- Earning Date
- CCCC 08-07-2025
- LPSN 08-11-2025
- Dividend Yield
- CCCC N/A
- LPSN N/A
- EPS Growth
- CCCC N/A
- LPSN N/A
- EPS
- CCCC N/A
- LPSN N/A
- Revenue
- CCCC $34,240,000.00
- LPSN $271,750,000.00
- Revenue This Year
- CCCC N/A
- LPSN N/A
- Revenue Next Year
- CCCC N/A
- LPSN $0.82
- P/E Ratio
- CCCC N/A
- LPSN N/A
- Revenue Growth
- CCCC 16.55
- LPSN N/A
- 52 Week Low
- CCCC $1.09
- LPSN $0.61
- 52 Week High
- CCCC $7.22
- LPSN $2.08
- Technical
- Relative Strength Index (RSI)
- CCCC 59.48
- LPSN 49.54
- Support Level
- CCCC $1.95
- LPSN $0.95
- Resistance Level
- CCCC $2.94
- LPSN $1.37
- Average True Range (ATR)
- CCCC 0.26
- LPSN 0.12
- MACD
- CCCC 0.00
- LPSN -0.01
- Stochastic Oscillator
- CCCC 51.52
- LPSN 26.90
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.